Mario Hassi

📢 Study Highlights: PSA Decline as a Predictor in mHSPC Treatment A retrospective multicenter study analyzed 633 patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide (2018-2023). PSA response at 3 months was strongly linked to outcomes: ✅ Complete Response (PSA ≤0.02 ng/ml): 27% of patients, 92% radiologic progression-free survival (rPFS) at 24 months. ⚠️ Partial Response (PSA >0.02-0.2 ng/ml): 42% of patients, 86% rPFS at 24 months. ❌ Incomplete Response (PSA >0.2 ng/ml): 31% of patients, 63% rPFS at 24 months, with nearly 50% progressing within 2 years. 🔑 Predictive factors for a complete PSA response: •Use of next-generation imaging. •PSA <50 ng/ml at diagnosis. 💡 Implications: Early PSA response after 3 months of treatment provides a powerful prognostic tool to guide therapy for mHSPC. Heterogeneity among patients and data quality remain key limitations pubmed.ncbi.nlm.nih.gov/3947…